评估人工智能增强型数字尿液细胞学在膀胱癌诊断中的应用。

IF 2.6 3区 医学 Q3 ONCOLOGY
Tien-Jen Liu, Wen-Chi Yang, Shin-Min Huang, Wei-Lei Yang, Hsing-Ju Wu, Hui Wen Ho, Shih-Wen Hsu, Cheng-Hung Yeh, Ming-Yu Lin, Yi-Ting Hwang, Pei-Yi Chu
{"title":"评估人工智能增强型数字尿液细胞学在膀胱癌诊断中的应用。","authors":"Tien-Jen Liu, Wen-Chi Yang, Shin-Min Huang, Wei-Lei Yang, Hsing-Ju Wu, Hui Wen Ho, Shih-Wen Hsu, Cheng-Hung Yeh, Ming-Yu Lin, Yi-Ting Hwang, Pei-Yi Chu","doi":"10.1002/cncy.22884","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the diagnostic effectiveness of the AIxURO platform, an artificial intelligence-based tool, to support urine cytology for bladder cancer management, which typically requires experienced cytopathologists and substantial diagnosis time.</p><p><strong>Methods: </strong>One cytopathologist and two cytotechnologists reviewed 116 urine cytology slides and corresponding whole-slide images (WSIs) from urology patients. They used three diagnostic modalities: microscopy, WSI review, and AIxURO, per The Paris System for Reporting Urinary Cytology (TPS) criteria. Performance metrics, including TPS-guided and binary diagnosis, inter- and intraobserver agreement, and screening time, were compared across all methods and reviewers.</p><p><strong>Results: </strong>AIxURO improved diagnostic accuracy by increasing sensitivity (from 25.0%-30.6% to 63.9%), positive predictive value (PPV; from 21.6%-24.3% to 31.1%), and negative predictive value (NPV; from 91.3%-91.6% to 95.3%) for atypical urothelial cell (AUC) cases. For suspicious for high-grade urothelial carcinoma (SHGUC) cases, it improved sensitivity (from 15.2%-27.3% to 33.3%), PPV (from 31.3%-47.4% to 61.1%), and NPV (from 91.6%-92.7% to 93.3%). Binary diagnoses exhibited an improvement in sensitivity (from 77.8%-82.2% to 90.0%) and NPV (from 91.7%-93.4% to 95.8%). Interobserver agreement across all methods showed moderate consistency (κ = 0.57-0.61), with the cytopathologist demonstrating higher intraobserver agreement than the two cytotechnologists across the methods (κ = 0.75-0.88). AIxURO significantly reduced screening time by 52.3%-83.2% from microscopy and 43.6%-86.7% from WSI review across all reviewers. Screening-positive (AUC+) cases required more time than negative cases across all methods and reviewers.</p><p><strong>Conclusions: </strong>AIxURO demonstrates the potential to improve both sensitivity and efficiency in bladder cancer diagnostics via urine cytology. Its integration into the cytopathological screening workflow could markedly decrease screening times, which would improve overall diagnostic processes.</p>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis.\",\"authors\":\"Tien-Jen Liu, Wen-Chi Yang, Shin-Min Huang, Wei-Lei Yang, Hsing-Ju Wu, Hui Wen Ho, Shih-Wen Hsu, Cheng-Hung Yeh, Ming-Yu Lin, Yi-Ting Hwang, Pei-Yi Chu\",\"doi\":\"10.1002/cncy.22884\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study evaluated the diagnostic effectiveness of the AIxURO platform, an artificial intelligence-based tool, to support urine cytology for bladder cancer management, which typically requires experienced cytopathologists and substantial diagnosis time.</p><p><strong>Methods: </strong>One cytopathologist and two cytotechnologists reviewed 116 urine cytology slides and corresponding whole-slide images (WSIs) from urology patients. They used three diagnostic modalities: microscopy, WSI review, and AIxURO, per The Paris System for Reporting Urinary Cytology (TPS) criteria. Performance metrics, including TPS-guided and binary diagnosis, inter- and intraobserver agreement, and screening time, were compared across all methods and reviewers.</p><p><strong>Results: </strong>AIxURO improved diagnostic accuracy by increasing sensitivity (from 25.0%-30.6% to 63.9%), positive predictive value (PPV; from 21.6%-24.3% to 31.1%), and negative predictive value (NPV; from 91.3%-91.6% to 95.3%) for atypical urothelial cell (AUC) cases. For suspicious for high-grade urothelial carcinoma (SHGUC) cases, it improved sensitivity (from 15.2%-27.3% to 33.3%), PPV (from 31.3%-47.4% to 61.1%), and NPV (from 91.6%-92.7% to 93.3%). Binary diagnoses exhibited an improvement in sensitivity (from 77.8%-82.2% to 90.0%) and NPV (from 91.7%-93.4% to 95.8%). Interobserver agreement across all methods showed moderate consistency (κ = 0.57-0.61), with the cytopathologist demonstrating higher intraobserver agreement than the two cytotechnologists across the methods (κ = 0.75-0.88). AIxURO significantly reduced screening time by 52.3%-83.2% from microscopy and 43.6%-86.7% from WSI review across all reviewers. Screening-positive (AUC+) cases required more time than negative cases across all methods and reviewers.</p><p><strong>Conclusions: </strong>AIxURO demonstrates the potential to improve both sensitivity and efficiency in bladder cancer diagnostics via urine cytology. Its integration into the cytopathological screening workflow could markedly decrease screening times, which would improve overall diagnostic processes.</p>\",\"PeriodicalId\":9410,\"journal\":{\"name\":\"Cancer Cytopathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cytopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cncy.22884\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cncy.22884","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:这项研究评估了 AIxURO 平台(一种基于人工智能的工具)的诊断效果,以支持膀胱癌管理中的尿液细胞学检查,这通常需要经验丰富的细胞病理学家和大量的诊断时间:方法:一名细胞病理学家和两名细胞技术专家审查了来自泌尿科患者的 116 张尿液细胞学切片和相应的全切片图像(WSI)。他们采用了三种诊断方式:显微镜检查、WSI 复查和根据巴黎尿液细胞学报告系统(TPS)标准进行的 AIxURO。对所有方法和审查人员的性能指标进行了比较,包括 TPS 指导下的诊断和二元诊断、观察者之间和观察者内部的一致性以及筛查时间:AIxURO提高了非典型尿路上皮细胞(AUC)病例的敏感性(从25.0%-30.6%提高到63.9%)、阳性预测值(PPV;从21.6%-24.3%提高到31.1%)和阴性预测值(NPV;从91.3%-91.6%提高到95.3%),从而提高了诊断准确性。对于疑似高级别尿路上皮癌(SHGUC)病例,它提高了敏感性(从 15.2%-27.3% 提高到 33.3%)、PPV(从 31.3%-47.4% 提高到 61.1%)和 NPV(从 91.6%-92.7% 提高到 93.3%)。二元诊断的灵敏度(从 77.8%-82.2% 提高到 90.0%)和 NPV(从 91.7%-93.4% 提高到 95.8%)均有所提高。在所有方法中,观察者间的一致性均为中等(κ = 0.57-0.61),在所有方法中,细胞病理学家的观察者内一致性高于两位细胞技术专家(κ = 0.75-0.88)。与显微镜检查相比,AIxURO 大幅缩短了筛查时间,在所有审查人员中,AIxURO 比显微镜检查缩短了 52.3%-83.2%,比 WSI 审查缩短了 43.6%-86.7%。在所有方法和审查人员中,筛查阳性(AUC+)病例比阴性病例需要更多时间:AIxURO 显示了通过尿液细胞学提高膀胱癌诊断灵敏度和效率的潜力。将其整合到细胞病理学筛查工作流程中可显著缩短筛查时间,从而改善整体诊断流程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating artificial intelligence-enhanced digital urine cytology for bladder cancer diagnosis.

Background: This study evaluated the diagnostic effectiveness of the AIxURO platform, an artificial intelligence-based tool, to support urine cytology for bladder cancer management, which typically requires experienced cytopathologists and substantial diagnosis time.

Methods: One cytopathologist and two cytotechnologists reviewed 116 urine cytology slides and corresponding whole-slide images (WSIs) from urology patients. They used three diagnostic modalities: microscopy, WSI review, and AIxURO, per The Paris System for Reporting Urinary Cytology (TPS) criteria. Performance metrics, including TPS-guided and binary diagnosis, inter- and intraobserver agreement, and screening time, were compared across all methods and reviewers.

Results: AIxURO improved diagnostic accuracy by increasing sensitivity (from 25.0%-30.6% to 63.9%), positive predictive value (PPV; from 21.6%-24.3% to 31.1%), and negative predictive value (NPV; from 91.3%-91.6% to 95.3%) for atypical urothelial cell (AUC) cases. For suspicious for high-grade urothelial carcinoma (SHGUC) cases, it improved sensitivity (from 15.2%-27.3% to 33.3%), PPV (from 31.3%-47.4% to 61.1%), and NPV (from 91.6%-92.7% to 93.3%). Binary diagnoses exhibited an improvement in sensitivity (from 77.8%-82.2% to 90.0%) and NPV (from 91.7%-93.4% to 95.8%). Interobserver agreement across all methods showed moderate consistency (κ = 0.57-0.61), with the cytopathologist demonstrating higher intraobserver agreement than the two cytotechnologists across the methods (κ = 0.75-0.88). AIxURO significantly reduced screening time by 52.3%-83.2% from microscopy and 43.6%-86.7% from WSI review across all reviewers. Screening-positive (AUC+) cases required more time than negative cases across all methods and reviewers.

Conclusions: AIxURO demonstrates the potential to improve both sensitivity and efficiency in bladder cancer diagnostics via urine cytology. Its integration into the cytopathological screening workflow could markedly decrease screening times, which would improve overall diagnostic processes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Cytopathology
Cancer Cytopathology 医学-病理学
CiteScore
7.00
自引率
17.60%
发文量
130
审稿时长
1 months
期刊介绍: Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信